Trial Number
339-23
Condition
Cystic Fibrosis
Participant Age Range
18 years to 65 years
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability and Efficacy of VX-522 in Subjects 18 Years of age and older with Cystic Fibrosis and CFTR Genotype Not Responsive to CFTR Modulator Therapy”
A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF).